-
08
2022
Caliway Announces Achievements in Revolutionary Fat Reduction Therapy
CBL-514 has demonstrated promising clinical effectiveness and safety in reducing local fat through a mechanism of adipocytes apoptosis.
-
04
2022
FDA grants IND approval for phase II for treating rare diseases
CBL-514 injection is suitable for treating rare diseases- Dercum's disease. Applications for U.S. Phase II IND was approved. Upcoming IPO in 2022.
-
08
2021
Caliway awarded patents for CBL-514 in the major market countries
CBL-514 has obtained more than 30 patents in major markets, including the United States, Europe, Canada, Australia, Taiwan, South Korea, Singapore, Russia and Mexico, etc.
-
05
2021
The phase IIa of CBL-514 injection was completed
Caliway announced the innovative abdominal fat reduction drug CBL-514 to meet primary and secondary endpoints in Phase IIa study.
